Dynavax Technologies (NASDAQ:DVAX) was upgraded by stock analysts at BidaskClub from a “hold” rating to a “buy” rating in a report released on Thursday, BidAskClub reports.

DVAX has been the subject of several other reports. ValuEngine raised shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. William Blair reaffirmed a “buy” rating on shares of Dynavax Technologies in a research note on Friday, August 16th. Zacks Investment Research downgraded shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a research note on Monday, November 11th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Dynavax Technologies in a research note on Thursday, November 7th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company’s stock. Dynavax Technologies has an average rating of “Buy” and a consensus target price of $12.63.

DVAX traded up $0.05 during midday trading on Thursday, hitting $5.88. The company had a trading volume of 453,800 shares, compared to its average volume of 1,314,191. Dynavax Technologies has a 52 week low of $2.60 and a 52 week high of $12.49. The company has a quick ratio of 4.09, a current ratio of 4.94 and a debt-to-equity ratio of 5.48. The company has a market capitalization of $488.93 million, a price-to-earnings ratio of -2.31 and a beta of 0.50. The stock’s 50 day moving average price is $4.66 and its 200 day moving average price is $4.50.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.10). Dynavax Technologies had a negative net margin of 519.95% and a negative return on equity of 399.60%. The company had revenue of $10.58 million during the quarter, compared to the consensus estimate of $10.31 million. During the same period last year, the firm posted ($0.65) earnings per share. The company’s revenue for the quarter was up 624.7% on a year-over-year basis. Research analysts predict that Dynavax Technologies will post -2.04 EPS for the current year.

Large investors have recently bought and sold shares of the company. Ladenburg Thalmann Financial Services Inc. increased its position in shares of Dynavax Technologies by 95.0% during the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,984 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 3,402 shares in the last quarter. Bank of Montreal Can increased its position in shares of Dynavax Technologies by 148.4% during the second quarter. Bank of Montreal Can now owns 7,440 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 4,445 shares in the last quarter. Wedbush Securities Inc. bought a new stake in shares of Dynavax Technologies during the second quarter worth about $42,000. M&T Bank Corp increased its position in shares of Dynavax Technologies by 29.5% during the second quarter. M&T Bank Corp now owns 13,685 shares of the biopharmaceutical company’s stock worth $54,000 after acquiring an additional 3,116 shares in the last quarter. Finally, Ingalls & Snyder LLC bought a new stake in shares of Dynavax Technologies during the third quarter worth about $52,000. 81.87% of the stock is owned by institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.

Featured Article: Sell-Side Analysts

Analyst Recommendations for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.